.jpg)
KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical Immunology
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced data from the Phase 1 clinical trials of oral, on-demand treatment KVD900 in patients with hereditary angioedema (HAE), have been published online by the Journal of Allergy and Clinical Immunology (JACI).
The objective of the Phase 1 studies was to evaluate the safety, tolerability, pharmacokinetics, and clinical pharmacology of KVD900, an orally administered inhibitor of plasma kallikrein in healthy adults. KVD900 was administered to 98 participants in total, and the data showed that KVD900 achieves near-complete plasma kallikrein inhibition within 30 minutes and was generally safe and well tolerated.
“We are pleased to see these data published in JACI to further describe our ongoing work to bring a safe, oral on-demand treatment option to the market for HAE patients,” said Andrew Crockett, Chief Executive Officer of KalVista. “These data show that KVD900 rapidly suppresses plasma kallikrein activity, a key mediator of HAE attacks, and may provide the early relief from HAE attack progression that represents a currently unmet need in orally administered management of the disease. These findings have since been further validated by the results of our Phase 2 clinical trial for KVD900.”
Additional details can be found in the manuscript, which is available in the “Articles in Press” section of the JACI website, located at: https://www.jacionline.org. JACI is an official journal of the American Academy of Allergy, Asthma, and Immunology.
About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021. KVD824 is in development for prophylactic treatment of HAE, with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.
For more information, please visit www.kalvista.com.